Please assess the completion status of the following clinical trial:

Trial Title: Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Spontaneous intracerebral hemorrhage as documented by head CT scan~* Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication~Exclusion Criteria:~* International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use~* History of von Willebrand disease~* Pregnancy~* Known hypersensitivity to DDAVP or desmopressin~* Active cardiovascular disease or unstable angina~* Hyponatremia or history of hyponatremia~* Current or historical deep venous thrombosis or pulmonary embolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- DDAVP (Type: EXPERIMENTAL): DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).